Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

GENALICE Prepares for Launch of Raw DNA Sequence Data Processing Software

Published: Friday, April 19, 2013
Last Updated: Friday, April 19, 2013
Bookmark and Share
Management team realignment.

GENALICE B.V. has announced the imminent release of the beta version of its first product, GENALICE MAP, to take place within the next few weeks.

MAP can process raw DNA data, produced by sequencers, in a fast, cost effective and reliable way and stores the data in a small file for easier manageability.

Major applications are DNA research and drug development of complex diseases such as cancer. In anticipation of this new phase of the company’s development the tasks within the management team have been rearranged.

Jos Lunenberg will now fulfill the role of CEO (Chief Executive Officer). Bert Reijmerink will now assume the position of CSO (Chief Strategy Officer). Co-founder Hans Karten remains CTO (Chief Technology Officer).

New phase, new organization
The management of GENALICE is passionate about contributing to improving the diagnosis and treatment methods for patients with complex DNA-related diseases.

The company was founded in 2011 by Bert Reijmerink and Hans Karten, who is highly experienced in the field of ‘high performance’, ‘high volume’ data processing and analysis.

In January last year, the team was strengthened by the arrival of Jos Lunenberg, an expert in marketing & sales management and business strategies within the life sciences industry.

In the initial phase of GENALICE the focus was on developing new products and finding investors. To this end, alliances were sought with scientists and managers from the top of the medical community and industry.

Consequently the launch of GENALICE’s first product is now imminent.

For a photo of Jos Lunenberg, CEO GENALICE (photographer: Bart Dykstra) please click this link: http://www.genalice.com/wp-content/uploads/2013/04/GEN-36-JL.jpg

"We believe we can bring a major breakthrough in DNA research with our product"
"GENALICE MAP can process raw data, produced by sequencers, rapidly, cost effectively and reliably," explains Hans Karten about the new product. "MAP accelerates this so-called alignment process two hundred-fold compared to existing methods. The required disk space for storing the data is a hundred times smaller than is common. Earlier this week we presented these breakthrough results at the annual Netherlands Bioinformatics Conference (NBIC 2013)".

Bert Reijmerink adds: "This gives scientists the opportunity for cheaper and faster DNA research and new drug development to tackle complex diseases such as cancer. The energy savings that we can realize are significant too. With the launch of MAP - in the summer of this year - we can bring about a major breakthrough in DNA research. For this phase we needed another type of CEO; one with knowledge and experience in the field of life sciences and healthcare. With his background as a molecular biologist and his broad and international experience in the life sciences industry, Jos Lunenberg is a logical choice. As of today, I will focus on the setting up strategic alliances and indirect sales models, so that we can continue to grow in the near future and develop new products to bring to the market”.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

KeyGene and GENALICE Join Forces
KeyGene purchased a license of GENALICE MAP, a groundbreaking new sequence-mapping tool to accelerate and improve DNA research.
Wednesday, October 30, 2013
GENALICE Prepares For Software Launch with Management Realignment
Company to launch raw DNA sequence data processing software.
Thursday, April 18, 2013
Scientific News
The Rise of 3D Cell Culture and in vitro Model Systems for Drug Discovery and Toxicology
An overview of the current technology and the challenges and benefits over 2D cell culture models plus some of the latest advances relating to human health research.
Grant Supports Project To Develop Simple Test To Screen For Cervical Cancer
UCLA Engineering announces funding from Bill and Melinda Gates Foundation.
Injecting New Life into Old Antibiotics
A new fully synthetic way to make a class of antibiotics called macrolides from simple building blocks is set to open up a new front in the fight against antimicrobial drug resistance.
Insight into Bacterial Resilience and Antibiotic Targets
Variant of CRISPR technology paired with computerized imaging reveals essential gene networks in bacteria.
Advancing Protein Visualization
Cryo-EM methods can determine structures of small proteins bound to potential drug candidates.
Alzheimer’s Protein Serves as Natural Antibiotic
Alzheimer's-associated amyloid plaques may be part of natural process to trap microbes, findings suggest new therapeutic strategies.
Slime Mold Reveals Clues to Immune Cells’ Directional Abilities
Study from UC San Diego identifies a protein involved in the directional ability of a slime mold.
How Do You Kill A Malaria Parasite?
Drexel University scientists have discovered an unusual mechanism for how two new antimalarial drugs operate: They give the parasite’s skin a boost in cholesterol, making it unable to traverse the narrow labyrinths of the human bloodstream. The drugs also seem to trick the parasite into reproducing prematurely.
Illuminating Hidden Gene Regulators
New super-resolution technique visualizes important role of short-lived enzyme clusters.
Supressing Intenstinal Analphylaxis in Peanut Allergy
Study from National Jewish Health shows that blockade of histamine receptors suppresses intestinal anaphylaxis in peanut allergy.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!